RxDoctor Payments Data

Jeffrey Miller, MD

Pain Medicine · Moore, OKNPI 1508905704

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (53.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Medtronic accounts for 78.3% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2023 at $12,131 and has fallen 72.3% since, to $3,365 in 2025. Among pain medicine clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$33,361in general payments, 2019–2025

Across 449 payments — averaging $74.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$26K
  • Abbott$2K
  • Forte Bio-pharma LLC$1K
  • BD$850
  • Saluda Medical Americas, Inc.$682
  • AbbVie$613
  • plus $2K from 23 others

What the payments were for

  • Speaking & faculty fees$17,90054%
  • Travel & lodging$2,9609%
  • Food & beverage$12,50137%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,361 in reported general payments places this provider in the 90th percentile of 68 pain medicine providers in Oklahoma.

See all pain medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$296,461
Medicare patients
533
Services billed
4,205

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,304$301,538
Buprenorphine433$91,429
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen2,229$62,010
PercocetOxycodone Hcl/Acetaminophen12$52,235
BelbucaBuprenorphine Hcl61$44,164
Xtampza ErOxycodone Myristate81$31,893
OxycontinOxycodone Hcl66$26,573
Nucynta ErTapentadol Hcl24$22,336
Oxycodone Hcl842$17,952
Pregabalin616$14,384
Morphine Sulfate ErMorphine Sulfate360$8,314
Hysingla ErHydrocodone Bitartrate14$5,391
ButransBuprenorphine16$5,185
Buprenorphine Hcl168$4,555
Fentanyl53$4,200

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er, Nucynta Er$189$98,393166 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 68 pain medicine providers in Oklahoma.

Other pain medicine in Moore

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →